Interobserver variability in rectum contouring in high-dose-rate brachytherapy for prostate cancer: A multi-institutional prospective analysis
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Chicas-Sett, R
- Rodriguez-Villalba, S
- Santos-Olias, M
- Soler-Catalan, P
- Arribas, L
Grupos
Abstract
PURPOSE: The aim of this study was to evaluate the interobserver variability (KW) of rectum contouring, and its dosimetric consequences, for high-dose-rate brachytherapy in patients with prostate cancer across multiple institutions. METHODS AND MATERIALS: Five radiation oncologists contoured rectums in 10 patients on transperineal ultrasound image sets after establishing a delineation consensus. The D-0.1cc, D-1cc, and D-2cc rectum volume parameters were determined. The mean, standard deviation, and range of each dose-volume histogram parameter were evaluated for each patient. The JOY was determined using the coefficient of variation, and the dosimetric impacts on the total dose were analyzed by estimating the biologically equivalent dose (EQD(2 alpha/beta) = 3). RESULTS: The interobserver coefficients of variation (+/- standard deviation) for the reported D-0.1cc, D-1cc, and D-2cc were 5 +/- 1.84%, 4 +/- 1.26%, and 4 +/- 1.33%, respectively. As for the impact on the total dose, the mean dose differences for D-0.1cc, D-1cc, and D-2cc were 10 Gy, 7.3 Gy, and 6.6 Gy, respectively. CONCLUSIONS: The D-2cc is robust as evident by the low IOV (<5%). However, some variability ranges almost overlap with the clinical threshold level, which may present dosimetric and clinical complications. General rectal contouring guidelines for prostate high-dose-rate brachytherapy are desirable to reduce discrepancies in delineation. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1538-4721, 1873-1449
- Tipo:
- Article
- Páginas:
- 208-213
- Factor de Impacto:
- 0,666 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Brachytherapy ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 6
Documentos
- No hay documentos
Filiaciones
Keywords
- Contouring; High-dose-rate brachytherapy; Interobserver variability; Prostate cancer
Proyectos asociados
MEDIDA DEL IMPACTO DE LA RADIOTERAPIA CON INTENCIÓN CURATIVA COMBINADA O NO CON TERAPIA HORMONAL SOBRE LA CALIDAD DE VIDA EN LA PRÁCTICA CLÍNICA EN EL CÁNCER DE PRÓSTATA LOCALIZADO. ESTUDIO VEPIC-ORT.
Investigador Principal: FRANCISCO JAVIER CELADA ÁLVAREZ
ONC-MA-1003 . 2016
PROSTATE CANCER OUTCOMES GLOBAL INITIATIVE TO COMPARE AND REDUCE VARIATION IN LOCALISED PROSTATE CANCER ("PCO-CRV").
Investigador Principal: FRANCISCO JAVIER CELADA ÁLVAREZ
PCO-CRV . 2019
ESTUDIO DESCRIPTIVO DEL PERFIL DEL PACIENTE CON CANCER DE PROSTATA EN CONSULTA DE ONCOLOGIA RADIOTERAPICA.
Investigador Principal: ALEJANDRO TORMO MICO
ONC-RT01-10 . 2011
ESTUDIO ALEATORIZADO MULTICÉNTRICO EN FASE III DE RADIOTERAPIA DE CORTA DURACIÓN SEGUIDA DE QUIMIOTERAPIA PREOPERATORIA DE LARGA DURACIÓN Y CIRUGÍA EN EL CÁNCER RECTAL PRIMARIO DE ALTO RIESGO EN COMPARACIÓN CON QUIMIORRADIOTERAPIA CONVENCIONAL Y CIRUGÍA Y OPTIMA QUIMIOTERAPIA ADYUVANTE.
Investigador Principal: JORGE APARICIO URTASUN
RAPIDO
ESTUDIO EPIDEMIOLÓGICO OBSERVACIONAL PROSPECTIVO DEL MANEJO DEL DOLOR EN PACIENTES ONCOLÓGICOS EN TRATAMIENTO RADIOTERÁPICO.
Investigador Principal: FRANCISCO JOSÉ MARTÍNEZ ARCELUS
GOR-ANA-2012-01
TRATAMIENTO RADIOTERÁPICO EN PACIENTES CON CÁNCER DE PRÓSTATA EN FUNCIÓN DEL NIVEL DE RIESGO CONFORME A LA PRÁCTICA CLÍNICA HABITUAL EN LOS SERVICIOS DE ONCOLOGÍA RADIOTERÁPICA ESPAÑOLES.
Investigador Principal: ERICA COLLADO BALLESTEROS
GIC-RAD-2013-01
ESTUDIO DE BRAQUITERAPIA ELECTRÓNICA PARA CARCINOMA CUTÁNEO BASOCELULAR.
Investigador Principal: JOSÉ PÉREZ CALATAYUD
BCCBRACHY
EFECTIVIDAD DE LOS NUEVOS TRATAMIENTOS PARA EL CÁNCER DE PRÓSTATA LOCALIZADO DE BAJO RIESGO.
Investigador Principal: ALEJANDRO TORMO MICO
TTOPRÓSTATA/OBS
Cita
Chicas R,Celada F,Roldan S,Rodriguez S,Santos M,Soler P,Ibanez B,Arribas L,Tormo A,Benlloch JM,Perez J. Interobserver variability in rectum contouring in high-dose-rate brachytherapy for prostate cancer: A multi-institutional prospective analysis. Brachytherapy. 2018. 17. (1):p. 208-213. IF:2,030. (3).